| Gene symbol | F | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001803.1 (5619..7521) | dbXrefs | |
| Description | Fusion protein (F) | ||||
| GTO ID | GTC2848 |
| Trial ID | NCT05127434 |
| Disease | Respiratory Syncytial Virus Infectious Disease |
| Altered gene | F |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1345 |
| Phase | Phase2|Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥60 Years of Age |
| Year | 2021 |
| Country | Argentina|Australia|Bangladesh|Belgium|Canada|Chile|Colombia|Costa Rica|Finland|Germany|Japan|Korea,Republic of|Mexico|New Zealand|Panama|Poland|Puerto Rico|Singapore|South Africa|Spain|China|United Kingdom|United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1345-P301 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1345 | |||||||||||
|
|||||||||||
| Cohort2: Placebo | |||||||||||
|
|||||||||||